Abstract
Current strategies to elicit cytolytic T cell responses specific for tumor-associated or over-expressed self antigens rely on multiple immunizations and in vitro expansion schemes. Here we report the in vivo induction of activated tumor-specific CD8+ CTL just 6 days after treatment with the IgM immune modulator B7-DC XAb. Antibody treatment of mice at the time of tumor challenge elicited potent CTL with a specificity that distinguished between MHC-compatible tumors. Remarkably, these effector cells were not generated by the extensive proliferation of naive CTL precursors, though their induction required CD4+ T cell help and classical B7 costimulatory signals. Tumor targets were recognized and lysed in an MHC-restricted, perforin-dependent manner, indicating that these rapidly induced effectors resemble traditionally defined CTL, despite the finding that strong increases in the expression of the effector/memory marker CD44 and the activation marker CD69 were not elicited. These CTL were induced in animals bearing well-established tumors and resulted in anti-tumor protection, underscoring the therapeutic potential of this type of effector T cell population in cancer patients.
Original language | English (US) |
---|---|
Pages (from-to) | 1827-1835 |
Number of pages | 9 |
Journal | European Journal of Immunology |
Volume | 37 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2007 |
Keywords
- Costimulatory molecules
- Cytotoxicity
- Dendritic cells
- T cells
- Tumor immunology
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology